Compounds > kmup 1
Page last updated: 2024-08-02 16:57:52

kmup 1

Description

KMUP 1: a potassium channel opener and stimulator of the NO/sGC/cGMP pathway; structure in first source [MeSH]

Cross-References

ID SourceID
PubMed CID10453764
SCHEMBL ID458792
MeSH IDM0404950

Synonyms (18)

Synonym
kmup1 cpd
kmup 1
kmup-1
81996-46-5
1h-purine-2,6-dione, 7-(2-(4-(2-chlorophenyl)-1-piperazinyl)ethyl)-3,7-dihydro-1,3-dimethyl-
7-(2-(4-(2-chlorophenyl)piperazinyl)ethyl)-1,3-dimethylxanthine
1x0h7wec5d ,
unii-1x0h7wec5d
SCHEMBL458792
DTXSID80440203
7-[2-[4-(2-chlorophenyl)piperazin-1-yl]ethyl]-1,3-dimethylpurine-2,6-dione
gtpl8896
(7-[2-[4-(2-chlorophenyl)piperazinyl]ethyl]-1,3-dimethylxanthine)
AKOS033007292
1254041-13-8
NIDVDYQCGWISJZ-UHFFFAOYSA-N
Q15634084
Z104874704

Bioassays (3)

Assay IDTitleYearJournalArticle
AID1345993Rat alpha1B-adrenoceptor (Adrenoceptors)2007The Prostate, Sep-15, Volume: 67, Issue:13
ISSN: 0270-4137		cGMP-enhancing- and alpha1A/alpha1D-adrenoceptor blockade-derived inhibition of Rho-kinase by KMUP-1 provides optimal prostate relaxation and epithelial cell anti-proliferation efficacy.
AID1345857Rat alpha1A-adrenoceptor (Adrenoceptors)2007The Prostate, Sep-15, Volume: 67, Issue:13
ISSN: 0270-4137		cGMP-enhancing- and alpha1A/alpha1D-adrenoceptor blockade-derived inhibition of Rho-kinase by KMUP-1 provides optimal prostate relaxation and epithelial cell anti-proliferation efficacy.
AID1345920Rat alpha1D-adrenoceptor (Adrenoceptors)2007The Prostate, Sep-15, Volume: 67, Issue:13
ISSN: 0270-4137		cGMP-enhancing- and alpha1A/alpha1D-adrenoceptor blockade-derived inhibition of Rho-kinase by KMUP-1 provides optimal prostate relaxation and epithelial cell anti-proliferation efficacy.

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (19.44)29.6817
2010's28 (77.78)24.3611
2020's1 (2.78)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other39 (100.00%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
chlorine
1
halide anion;
monoatomic chlorine		cofactor;
Escherichia coli metabolite;
human metabolite		2011201113.0low000010
nitrates
1
monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		2006200618.0low000100
nitrites
2
monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species		human metabolite2006201613.0low000110
xanthine
2
xanthineSaccharomyces cerevisiae metabolite2001201416.5low000110
1h-(1,2,4)oxadiazolo(4,3-a)quinoxalin-1-one
1
oxadiazoloquinoxalineEC 4.6.1.2 (guanylate cyclase) inhibitor2001200123.0low000100
4-aminopyridine
1
aminopyridine;
aromatic amine		avicide;
orphan drug;
potassium channel blocker		2005200519.0low000100
theophylline
1
dimethylxanthineadenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent		201620168.0low000010
chelerythrine
1
benzophenanthridine alkaloid;
organic cation		antibacterial agent;
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor		2011201113.0low000010
doxazosin
1
aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines		alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent		2009200915.0low000100
glyburide
1
monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent		2001200123.0low000100
isoproterenol
1
catechols;
secondary alcohol;
secondary amino compound		beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent		2010201014.0low000100
pinacidil
1
pyridines2012201212.0low000010
methylene blue
1
organic chloride saltacid-base indicator;
antidepressant;
antimalarial;
antimicrobial agent;
antioxidant;
cardioprotective agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 4.6.1.2 (guanylate cyclase) inhibitor;
fluorochrome;
histological dye;
neuroprotective agent;
physical tracer		2001200123.0low000100
quinoxalines
1
mancude organic heterobicyclic parent;
naphthyridine;
ortho-fused heteroarene		2001200123.0low000100
monocrotaline
2
pyrrolizidine alkaloid2010201412.0low000110
barium chloride
1
barium salt;
inorganic chloride		potassium channel blocker2011201113.0low000010
ng-nitroarginine methyl ester
2
alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound		EC 1.14.13.39 (nitric oxide synthase) inhibitor2001201217.5low000110
simvastatin
2
delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic)		EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug		201420169.0low000020
atorvastatin
1
aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic)		environmental contaminant;
xenobiotic		201620168.0low000010
cromakalim
1
2001200123.0low000100
clarithromycin
1
macrolide antibioticantibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic		2014201410.0low000010
tamsulosin
1
5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamidealpha-adrenergic antagonist;
antineoplastic agent		2007200717.0low000100
mevalonic acid
1
3,5-dihydroxy-3-methylpentanoic acid201520159.0low000010
y 27632
1
aromatic amide201520159.0low000010
oxadiazoles
1
2001200123.0low000100
7-(2-(4-(4-nitrobenzene)piperazinyl)ethyl)-1,3-dimethylxanthine
1
2006200618.0medium000100
endothelin-1
2
201420159.5low000020
piperidines
36
2001202011.6high00011250
ascorbic acid
1
ascorbic acid;
vitamin C		coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent		201520159.0low000010
cyclic gmp
11
3',5'-cyclic purine nucleotide;
guanyl ribonucleotide		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite		2001202013.2medium000560
sildenafil citrate
4
citrate saltEC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent		2002201514.5low000220
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Adenoma, Prostatic0
2
2014201410.0low000020
Age-Related Osteoporosis0
1
2013201311.0low000010
Airway Remodeling0
1
2012201212.0low000010
Allergic Reaction0
1
2012201212.0low000010
Allodynia0
1
2014201410.0low000010
Alloxan Diabetes0
2
201720186.5low000020
Alveolitis, Fibrosing0
1
2014201410.0low000010
Angiospasm, Intracranial0
1
2012201212.0low000010
Anoxemia0
1
201520159.0low000010
Body Weight0
2
201420169.0low000020
Cancer of Pituitary0
1
201520159.0low000010
Cancer of Prostate0
1
2009200915.0low000100
Cardiac Hypertrophy0
1
2010201014.0low000100
Cardiomegaly0
1
2010201014.0low000100
Chronic Disease0
1
2010201014.0low000100
Chronic Illness0
1
2010201014.0low000100
Chronic Kidney Failure0
1
202020204.0low000010
Cirrhosis0
2
2010201710.5low000110
Diabetic Glomerulosclerosis0
1
201720177.0low000010
Diabetic Nephropathies0
1
201720177.0low000010
Disease Models, Animal0
6
2010202010.0low000150
Experimental Lung Inflammation0
2
2012201411.0low000020
Fatty Liver0
1
201620168.0low000010
Fibrosis0
2
2010201710.5low000110
Heart Disease, Ischemic0
1
201920195.0low000010
Hemorrhage, Subarachnoid0
1
2012201212.0low000010
Hyperlipoproteinemia0
1
201520159.0low000010
Hyperlipoproteinemias0
1
201520159.0low000010
Hypersensitivity0
1
2012201212.0low000010
Hypertension, Pulmonary0
4
2010201511.8low000220
Hypertrophy0
1
201520159.0low000010
Hypertrophy, Left Ventricular0
1
2012201212.0low000010
Hypertrophy, Right Ventricular0
2
2010201412.0low000110
Hypoxia0
1
201520159.0low000010
Inflammation0
2
2006201414.0low000110
Innate Inflammatory Response0
2
2006201414.0low000110
Kidney Failure, Chronic0
1
202020204.0low000010
Left Ventricular Hypertrophy0
1
2012201212.0low000010
Liver Steatosis0
1
201620168.0low000010
Muscle Contraction0
3
2007201513.3low000210
Muscle Relaxation0
2
2002200421.0low000200
Myocardial Ischemia0
1
201920195.0low000010
Nerve Pain0
1
2014201410.0low000010
Neuralgia0
1
2014201410.0low000010
Osteoporosis0
1
2013201311.0low000010
Peripheral Nerve Injuries0
1
2012201212.0low000010
Peripheral Nerve Injury0
1
2012201212.0low000010
Pituitary Neoplasms0
1
201520159.0low000010
Pneumonia0
2
2012201411.0low000020
Prostatic Hyperplasia0
2
2014201410.0low000020
Prostatic Neoplasms0
1
2009200915.0low000100
Pulmonary Fibrosis0
1
2014201410.0low000010
Pulmonary Hypertension0
4
2010201511.8low000220
Subarachnoid Hemorrhage0
1
2012201212.0low000010
Vascular Calcification0
1
202020204.0low000010
Vascular Diseases0
1
201820186.0low000010
Vasospasm, Intracranial0
1
2012201212.0low000010

Safety/Toxicity (2)

ArticleYear
Xanthine-derived KMUP-1 reverses glucotoxicity-activated Kv channels through the cAMP/PKA signaling pathway in rat pancreatic β cells.
Chemico-biological interactions, , Jan-05, Volume: 279		2018
KMUP-1 attenuates serum deprivation-induced neurotoxicity in SH-SY5Y cells: roles of PKG, PI3K/Akt and Bcl-2/Bax pathways.
Toxicology, , Jan-31, Volume: 268, Issue:1-2		2010

Long-term Use (2)

ArticleYear
Theophylline-Based KMUP-1 Improves Steatohepatitis via MMP-9/IL-10 and Lipolysis via HSL/p-HSL in Obese Mice.
International journal of molecular sciences, , Aug-17, Volume: 17, Issue:8		2016
Endothelial nitric oxide synthase-enhancing G-protein coupled receptor antagonist inhibits pulmonary artery hypertension by endothelin-1-dependent and endothelin-1-independent pathways in a monocrotaline model.
The Kaohsiung journal of medical sciences, , Volume: 30, Issue:6		2014